Hepatic steatosis in overweight/obese females: New screening method for those at risk

Table 1 Anthropometric, clinical, laboratory and ultrasound data of the study population

Variables [females (82)]	Median (Range) mean ± SD		P-value
	IR present (52)	IR absent (30)
BMI (kg/m2)	33 (25-53.7)	32 (25.6-39.7)	0.78
Overweight (n)	7	6	0.6
Obesity 1° grade (n)	23	15	0.8
Obesity 2° (n)	12	9	0.7
Obesity 3° (n)	10	0	0.01a
HS score at US	1 (0-3)	2 (0-3)	0.005
DBP (mmHg)	90 (65-110)	80 (60-110)	0.03
SBP (mmHg)	120 (100-170)	135 (110-180)	0.0008
Triglycerides (mg/dL)	141 (25-386)	113 (41-249)	0.11
HDL (mg/dL)	48.2 ± 8.6	50.1 ± 10.1	0.36
Uric acid (mg/dL)	4.3 (2.7-8.2)	4.4 (2.7-7.6)	0.6
ALT (U/L)	22 (11-117)	22 (12-53)	0.9
hs-CRP (mg/L)	2.4 (0.2-11.7)	1.6 (0.3-6.2)	0.71
SLD at US (mm)	115 (92-150)	102 (90-127)	0.0001
MS (n)	18	6	0.0001
Menopause (n)	20	11	0.9

^aFisher’s exact test. IR: Insulin resistance; BMI: Body mass index; HS: Hepatic steatosis at US; US: Ultrasonography; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; HDL: High-density lipoprotein-cholesterol; ALT: Alanine aminotransferase; hs-CRP: High sensibility C-reactive protein; SLD: Spleen longitudinal diameter at US; MS: Metabolic syndrome; n: No. of subjects.